News
Cancer Horizons
All News
Blogs
Caregiving
Diet and Exercise
Financial
Psychosocial
Recipes
Sexual Health
Side Effect
Sponsored
Survivorship
Videos
All Videos
CURE Connections
CURE Expert Connections®
CURE Speaking Out
CURE TV
Educated Patient Sound Bites
On Demand: Award Programs
On Demand: Patient Summits
On Demand: Webinars
Conferences
Conference Coverage
Conference Listing
Events
CURE Adventures
CURE Awards
Educated Patient Summits
Educated Patient Webinars
Resources
Advocacy Groups
Art Gallery
CURE Ambassador Program
Clinical Trial Corner
Educated Patient Research Updates
Journey
Partners
Podcasts
Publications
Share Your Story
Subscribe
CURE Magazine
HEAL Magazine
Sign Up for eNews

logo
Spotlight
Blogs
Cancer Horizons
Clinical Trial Corner
Publications
Recipes
Videos
Cancer Type
Bladder
Breast
CLL
Kidney
Lung
MCL
Ovarian
Prostate
Skin
About CURE
Press Releases
Share Your Story
Write for CURE
Cancer Horizons
All News
Blogs
Caregiving
Diet and Exercise
Financial
Psychosocial
Recipes
Sexual Health
Side Effect
Sponsored
Survivorship
All Videos
CURE Connections
CURE Expert Connections®
CURE Speaking Out
CURE TV
Educated Patient Sound Bites
On Demand: Award Programs
On Demand: Patient Summits
On Demand: Webinars
Conference Coverage
Conference Listing
CURE Adventures
CURE Awards
Educated Patient Summits
Educated Patient Webinars
Advocacy Groups
Art Gallery
CURE Ambassador Program
Clinical Trial Corner
Educated Patient Research Updates
Journey
Partners
Podcasts
Publications
Share Your Story
CURE Magazine
HEAL Magazine
Sign Up for eNews
Advertisement
Bladder Cancer
| Brain Cancer
| Breast Cancer
| Childhood Cancers
| Gastric Cancer
| Gynecologic Cancer
| Head & Neck Cancer
| Immunotherapy
| Kidney Cancer
| Leukemia
| Liver Cancer
| Lung Cancer
| Lymphoma Cancer
| MDS
| MPN
| Melanoma
| Mesothelioma
| Myeloma
| Prostate Cancer
| Rare Cancers
| Sarcoma
| Skin Cancer
| Testicular Cancer
| Thyroid Cancer
| Waldenström Macroglobulinemia
View All >>
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Childhood Cancers
  • Gastric Cancer
  • Gynecologic Cancer
  • Head & Neck Cancer
  • Immunotherapy
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma Cancer
  • MDS
  • MPN
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Prostate Cancer
  • Rare Cancers
  • Sarcoma
  • Skin Cancer
  • Testicular Cancer
  • Thyroid Cancer
  • Waldenström Macroglobulinemia

SPOTLIGHT -

Blogs
| Cancer Horizons
| Clinical Trial Corner
| Publications
| Recipes
| Videos

Three-Drug Regimen Boosts Outcomes in HPV-Related Cancers

Jan 4, 2023
Brielle Benyon
Article

A novel three-drug combination bested standard-of-care regimens for patients with human papillomavirus-related cancers, according to phase 2 study results.

The novel drug combination of PDS0101 plus M9241 and bintrafusp alfa is improving outcomes in patients with human papillomavirus (HPV)-related cancers, according to findings from a phase 2 clinical trial reported by PDS Biotechnology, the manufacturer of PDS0101, in a press release.

The trial, which was conducted at the Center for Cancer Research at the National Cancer Institute (located near Washington, D.C.), involved 51 patients with advanced HPV-positive anal, cervical, head and neck, vaginal and vulvar cancers who were not previously treated with a checkpoint inhibitor or whose cancer did not respond or stopped responding to a checkpoint inhibitor. All patients enrolled in the study previously received chemotherapy, and most (90%) received radiation.

In the 29 patients whose disease did not respond to checkpoint inhibition (checkpoint refractory) and were given the three-drug combination, the average overall survival (time from treatment until death of any cause) was 29 months. Historically, this group of patients has had an average overall survival of three to four months, PDS Biotechnology reported in the press release.

Eight patients with checkpoint refractory disease received the optimal dose of PDS0101 plus M9241 and bintrafusp alfa. Of those patients, the objective response rate (percentage of patients whose disease shrinks as a result of treatment) was 63% (five patients). With the current standard of care, the average objective response rate tends to be less than 10%.

In patients who never received checkpoint inhibition (checkpoint inhibition naïve), 75% were still alive at a follow-up of 27 months, so the average overall survival has not yet been reached. Prior data showed that these patients typically have an average overall survival of seven to 11 months.

The objective response rate for checkpoint naïve patients was 88% — much higher than the average of 25%, which is seen with Food and Drug Administration (FDA)-approved checkpoint blockades for patients with HPV-related cancers.

“The expanded data continue to demonstrate the durability and tolerability of the PDS0101-based triple combination therapy in advanced HPV-positive cancers, an extremely challenging population of refractory and previously untreatable HPV-positive patients,” said Dr. Frank Bedu-Addo, president and CEO of PDS Biotech, in the press release.

Slightly less than half (48%) of patients experienced moderate treatment-related side effects from the three-drug regimen, and 4% experienced severe side effects. For patients receiving checkpoint inhibition plus chemotherapy for HPV-related cancers, approximately 70% experienced moderate side effects, according to the release.

Of note, PDS0101 is also being studied in combination with Keytruda (pembrolizumab) for patients with HPV-related head and neck cancer.

“We are pleased to see the continued consistency in the data with each update and we look forward to meeting with the FDA to discuss the registrational pathway,” concluded Bedu-Addo.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Dr. Chapman-Davis in an interview with CURE
Dr. Michael Moore
Dr. Michael Moore
Dr. Michael Moore
Dr. Michael Moore
Related Content

Saying Goodbye to Caring Cancer Health Care Providers

September 21st 2023

Author, Five-Time Cancer Survivor Shares His Experiences in New Book

August 10th 2023

What Cancer Taught Me

September 2nd 2023

A Powerful Voice in Head and Neck Cancer

April 16th 2020

Solid Cancer Approvals from Summer 2023

September 1st 2023

FDA Approval of Jemperli Plus Chemo ‘Changed the Game’ for Endometrial Cancer

August 25th 2023

Saying Goodbye to Caring Cancer Health Care Providers

September 21st 2023

Author, Five-Time Cancer Survivor Shares His Experiences in New Book

August 10th 2023

What Cancer Taught Me

September 2nd 2023

A Powerful Voice in Head and Neck Cancer

April 16th 2020

Solid Cancer Approvals from Summer 2023

September 1st 2023

FDA Approval of Jemperli Plus Chemo ‘Changed the Game’ for Endometrial Cancer

August 25th 2023

Saying Goodbye to Caring Cancer Health Care Providers

September 21st 2023

Author, Five-Time Cancer Survivor Shares His Experiences in New Book

August 10th 2023

What Cancer Taught Me

September 2nd 2023

A Powerful Voice in Head and Neck Cancer

April 16th 2020

Solid Cancer Approvals from Summer 2023

September 1st 2023

FDA Approval of Jemperli Plus Chemo ‘Changed the Game’ for Endometrial Cancer

August 25th 2023
Related Content
Advertisement

cartoon drawing of cancer survivor and blogger, Kelly Irvin

Saying Goodbye to Caring Cancer Health Care Providers

September 21st 2023
Article

Rachelle’s unexpected departure reminded me I need to express my appreciation to these special, beloved providers now.

Read More


Bill C. Potts holding his small dog, Pippa | Photo credit: Sarah Potts

Author, Five-Time Cancer Survivor Shares His Experiences in New Book

August 10th 2023
Podcast

Bill C. Potts, author and five-time cancer survivor, lends his experience and tips about cancer to others in his book, “Up for the Fight.”

Listen


Multiple exposure portrait of a woman. The sun behind the clouds. Emotional intelligence concept. | Image credit: © - primipil -© - stock.adobe.com

What Cancer Taught Me

September 2nd 2023
Article

I faced cancer thrice and chose life each time — not because of some flowery will to live, but because I’m stubborn and wanted to prove that cancer is not the boss of me.

Read More


Site Logo

A Powerful Voice in Head and Neck Cancer

April 16th 2020
Podcast

This week on the CURE Talks Cancer podcast, we spoke with voice actor Rob Paulsen, who was diagnosed with stage 3 metastatic squamous cell carcinoma in 2016, about how his experience helped him find a reason to smile, even when times get tough.

Listen


FDA approved

Solid Cancer Approvals from Summer 2023

September 1st 2023
Article

Here’s a look back at the therapies for solid cancers that gained FDA approval this summer.

Read More


FDA approval: What you need to know

FDA Approval of Jemperli Plus Chemo ‘Changed the Game’ for Endometrial Cancer

August 25th 2023
Article

Jemperli plus chemotherapy has been approved for the treatment of adults with primary advanced or recurrent mismatch repair deficient (dMMR) or microsatellite instability-high endometrial cancer.

Read More

About
Advertise / Support
Contact
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.